Biological E

Covid-19 development round-up: February 18, 2022

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

                                       
Medigen’s protein subunit…

Mentions:
Covid-19, vaccines, drugs, Medigen, AstraZeneca, Biological E, Moderna, Novavax, Abogen, Walvax, Gamaleya Institute, WHO, Afrigen, Pfizer, BioNTech, COVAX, Gavi, Merck, Gilead, Roche, Shionogi
Read more
Covid-19 development round-up: February 11, 2022

The state of the fight: 

A Lilly mAb active against Omicron won a U.S. FDA emergency use nod.
  Novavax’s shot proved 80% efficacious in adolescents ages 12-17, according to a Phase 3 readout.
  Vaxxinity’s UB-612 vaccine candidate performed better against Omicron than an mRNA-based comparator jab.

 

AUTHORIZED VACCINES

 
J&J’s single-dose shot was only 53% efficacious against moderate to severe Covid-19 (28 days post-injection) in a final analysis…

Mentions:
Covid-19, vaccines, drugs, J&J, Novavax, FDA, Pfizer, BioNTech, Bharat Biotech, CNBG, Sinopharm, Gamaleya Institute, Sinovac, EMA, AstraZeneca, Walvax, Moderna, Biological E, African Union, COVAX, WHO, ACT-A, Lilly, Gilead, Merck, GSK, Vir, Regeneron, Roche, DNDi, Novartis
Read more
Covid-19 development round-up: October 1, 2021

The state of the fight: 

COVAX will overhaul its vaccine allocation methodology.
  An investigational antiviral pill from Merck and Ridgeback Biotherapeutics cut the rate of hospitalizations or death some 50% in a Phase 3 trial.
  India plans to resume Covid-19 vaccine exports by the end of October.

 

Approved or authorized vaccines

 
The AstraZeneca/Oxford Covid-19 shot demonstrated 74% efficacy against symptomatic disease 15 days or more after a second…

Mentions:
Covid-19, drugs, vaccines, AstraZeneca, Pfizer, BioNTech, Moderna, Gamaleya Institute, EMA, J&J, Janssen, FDA, Sinovac, Sanofi, GSK, IVI, SII, Novavax, WHO, NIAID, Biological E, Takeda, CanSino, Butantan Institute, CNBG, Sinopharm, COVAX, Gavi, Regeneron, Roche, Vir, Merck
Read more
Covid-19 development round-up: September 24, 2021

The state of the fight: 

CanSino and Pfizer/BioNTech released positive news on their respective vaccines in children.
  WHO added Regeneron and Roche’s monoclonal antibody cocktail to its list of recommended therapeutics.
  California’s NantWorks plans a $200M investment to produce Covid-19 and other vaccines in South Africa. Approved or authorized vaccines

 
Pfizer and BioNTech touted positive topline results from a Phase 2/3 trial in children ages 5-11 of…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, BBIL, WHO, EMA, FDA, Moderna, J&J, Janssen, CanSino, Novavax, SII, BioCubaFarma, Gamaleya Institute, AstraZeneca, Valneva, Inovio, Biological E, COVAX, CNBG, Sinopharm, Regeneron, Roche, Gilead, Lilly
Read more
Covid-19 development round-up: September 2, 2021

The state of the fight: 

The U.S. FDA set a September date to discuss Pfizer/BioNTech boosters while E.U. officials saw “no urgent need” for boosters in the already vaccinated.
  Recruitment started in India for a late-stage trial of Serum Institute of India’s Covovax in children, and Biological E won approval to study its Corbevax in children.
  Prehospital antiplatelet therapy (such as aspirin) was associated with significantly lower in-hospital mortality in some…
Mentions:
Covid-19, vaccines, drugs, BBIL, Bharat Biotech, Moderna, Pfizer, BioNTech, Sinovac, CNBG, Sinopharm, Walvax, CanSino, CDC, FDA, Nanogen, J&J, Biological E, SII, SK Bioscience, GSK, AstraZeneca, AVAT, COVAX, UNICEF, Lilly, Regeneron, Roche
Read more
Covid-19 development round-up: July 30, 2021

The state of the fight: 

Regeneron and Roche’s REGEN-COV became the first antibody drug to score U.S. FDA clearance for post-exposure prophylaxis of Covid-19.
  Six-month data on Pfizer/BioNTech’s vaccine showed continuing high efficacy against severe disease.
  Antibody levels induced by Sinovac’s vaccine dropped sharply six months after completion of a two-dose regimen, according to new data.   Approved or authorized vaccines

New, six-month Pfizer/BioNTech vaccine…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Moderna, J&J, AstraZeneca, WHO, FDA, Gamaleya Institute, SII, BBIL, CanSino, Sinovac, Novavax, Biological E, CNBG, UNITAID, MPP, Africa CDC, Gavi, World Bank, Biovac, UNICEF, COVAX, Regeneron, Roche, Lilly, Gilead, GSK, Vir
Read more
Covid-19 development round-up: May 21, 2021

The state of the hunt:

J&J, Moderna and Pfizer/BioNTech pledged to provide 3.5 billion vaccine doses to LMICs at low cost.
  Sanofi touted favorable interim Phase 2 results for its protein-based vaccine candidate.
  Serum Institute of India pushed back its timeline to resume exporting vaccine doses to COVAX.

 

Approved or authorized vaccines

 
India’s review of bleeding and clotting events following immunization found a minuscule risk of those…

Mentions:
Covid-19, vaccines, drugs, SII, AstraZeneca, BBIL, WHO, J&J, Pfizer, BioNTech, Sinovac, Gamaleya Institute, Moderna, CanSino, CNBG, Sinopharm, Zydus Cadila, Sanofi, GSK, SK Bioscience, Emergent BioSolutions, Biological E, COVAX, Gavi, UNICEF, Lilly, Vir
Read more
Covid-19 development round-up: February 12, 2021

The state of the hunt:

Russia’s Sputnik V vaccine has reportedly been authorized in 26 countries.
  SAGE recommended that all countries proceed with planned rollouts of the AstraZeneca/Oxford jab, while the Africa CDC offered more cautious guidance, amid reports of low efficacy against viral variants.
  Tanzania has no plans to mount a Covid-19 immunization campaign.

 

Vaccines


Approved or authorized vaccines

SAGE backs AZ jab in all…

Mentions:
Covid-19, vaccines, drugs, WHO, SAGE, AstraZeneca, Oxford University, Africa CDC, SK Bioscience, Pfizer, BioNTech, Sinovac, Butantan Institute, Lekhim, Gamaleya Institute, EMA, CanSino, SII, Moderna, BBIL, J&J, Janssen, CureVac, Takis, Rottapharm Biotech, Razi Vaccine and Serum Research Institute, United Biomedical, Covaxx, ImmunityBio, NantKwest, FDA, Government Pharmaceutical Organization, Mahidol University, PATH, Evonik, IDT Biologika, Biological E, CNBG, Sinopharm, Wockhardt, EC, Providence Therapeutics, UNICEF, COVAX, COVAX AMC, AU, AVATT, Siam Bioscience, Lilly, EUAs, mAbs, Regeneron, Gilead, Roche, ASM, NIH, Synairgen, Corvus Pharmaceuticals, Veru, Eiger BioPharmaceuticals, Ichilov Hospital
Read more
Covid-19 development round-up: August 14, 2020

The state of the hunt:

Moderna inked a $1.5 billion, 100-million-shot supply deal with the U.S. government for its mRNA vaccine candidate.
  The EU sealed a 400-million-dose vaccine deal with AstraZeneca and agreed to a framework with J&J for up to 400 million more.
  Biological E will produce the investigational vaccine from J&J’s Janssen subsidiary.

 

Vaccines

Clinical trials:

Moderna and Pfizer/BioNTech took steps to modify the…

Mentions:
Covid-19, drugs, vaccines, diagnostics, FDA, NIAID, BARDA, Moderna, AstraZeneca, J&J, Janssen, Biological E, Pfizer, BioNTech, Fosun Pharma, CNBG, CanSino, Sinovac, UVRI, Imperial College, Arcturus, ReiThera, Vaxart, IIBR, CEPI, SK Bioscience, Novavax, AGC Biologics, EC, EU, Gavi, WHO, COVAX, Fiocruz, Lemann Foundation, Carlos Slim, Walvax, Dynvax, BMGF, WUSTL, PDS Biotech, Farmacore, Gamaleya, RDIF, Tecpar, CureVac, Gilead, Zydus Cadila, Romark, Appili, Pharming, Daewoong, UNION therapeutics, TFF, Vir Biotechnology, Molecular Partners, Genexine, NeoImmuneTech, Chrysalis, Verona Pharma, GigaGen, Omeros, Humanigen, Innate Pharma, Pluristem, Enlivex, Aclaris Therapeutics, Blade Therapeutics, CytoDyn, SAB Biotherapeutics, Lilly, Regeneron, Oxford Nanapore, Mayo Clinic
Read more
Covid-19 development round-up: July 31, 2020

The state of the hunt:

Moderna’s and Pfizer/BioNTech’s vaccines entered 30,000-participant late-stage trials in the United States.
  Britain and the United States entered supply deals for at least 160 million doses of the GSK/Sanofi vaccine candidate.
  Gavi identified 92 LMICs eligible for its COVAX Advance Market Commitment.

 

Vaccines

Clinical trials:

Moderna reaches Phase 3: The Massachusetts-based company has begun dosing in a study of its…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Pfizer, BioNTech, GSK, Sanofi, Moderna, J&J, Janssen, Gavi, Gamaleya, SII, Bharat Biotech, Genexine, Kalbe Farma, Vector Center, Bavarian Nordic, Adaptvac, ExpreS2ion, NextGen, Chumakov Center, Amyris, IDRI, AstraZeneca, Oxford University, Emergent, BARDA, Fujifilm Diosynth, BIOCAD, BIOCAD, UW, HDT Bio, EuBiologics, Intravacc, Celonic. Metaclipse, NAIAD, Medicanova, Biocomo, Heat Biologics, COVAX, World Bank, Biological E, MIT, Gilead, EC, AI Therapeutics, Immunic, Evotec, Sorrento, Can-Fite, NeoImmuneTech, ExeVir, VIB, Immunome, Cipla, Glenmark, Zydus Cadila, Roche, Genentech, BD, MSF, Cepheid, Bio-Manguinhos
Read more
Subscribe to Biological E